MKI67 and breast carcinoma: In a study by Qian et al., the clinical model, including pre-NAC T-stage, ER, Her2, and Ki-67, demonstrated good performance in predicting pCR in breast cancer with an AUC of 0.79 in TC (Qian et al., 2022).